{"id":"tocilizumab-plus-methotrexate","safety":{"commonSideEffects":[{"rate":null,"effect":"Infection (including serious infections)"},{"rate":null,"effect":"Elevated liver enzymes"},{"rate":null,"effect":"Neutropenia"},{"rate":null,"effect":"Gastrointestinal disturbances"},{"rate":null,"effect":"Headache"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Tocilizumab is a monoclonal antibody that binds to IL-6 receptors (both membrane-bound and soluble forms), blocking the pro-inflammatory cytokine IL-6 from activating immune cells. Methotrexate is a disease-modifying antirheumatic drug (DMARD) that inhibits dihydrofolate reductase, reducing nucleotide synthesis and thereby suppressing T-cell and B-cell proliferation. Together, this combination targets inflammation through complementary mechanisms.","oneSentence":"Tocilizumab blocks IL-6 receptor signaling to reduce inflammation, while methotrexate inhibits dihydrofolate reductase to suppress immune cell proliferation.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:13:05.876Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Rheumatoid arthritis (moderate to severe, active disease)"}]},"trialDetails":[{"nctId":"NCT06941376","phase":"PHASE2","title":"An Open-Label Study of Effectiveness of Immunomodulatory Medications for Patients With Relapsing Polychondritis","status":"RECRUITING","sponsor":"University of Pennsylvania","startDate":"2025-08-01","conditions":"Relapsing Polychondritis","enrollment":20},{"nctId":"NCT07077486","phase":"PHASE4","title":"Effects of Telitacicept vs Cyclophosphamide on Lupus Related Interstitial Lung Disease","status":"RECRUITING","sponsor":"Tongji Hospital","startDate":"2025-08-25","conditions":"Lupus or SLE, Interstitial Lung Disease, Systemic Lupus Erythematosus","enrollment":100},{"nctId":"NCT07080125","phase":"","title":"A Study Using a Disease Registry to Observe the Long-term Effects of Nintedanib in People With Scleroderma-related Lung Fibrosis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Boehringer Ingelheim","startDate":"2025-06-17","conditions":"Interstitial Lung Diseases, Systemic Sclerosis Associated Interstitial Lung Disease","enrollment":2000},{"nctId":"NCT07138898","phase":"PHASE2","title":"Immunosuppressant Management in Rheumatology Patients Undergoing Elective Total Shoulder Arthroplasty","status":"NOT_YET_RECRUITING","sponsor":"NYU Langone Health","startDate":"2025-09","conditions":"Rheumatic Disease","enrollment":80},{"nctId":"NCT02714634","phase":"PHASE4","title":"Clinical Trial Evaluating Methotrexate or Leflunomide + Targeted Therapy Versus Methotrexate or Leflunomide + Sulfasalazine + Hydroxychloroquine in Patients With Rheumatoid Arthritis and Insufficient Response to Methotrexate or Leflunomide","status":"RECRUITING","sponsor":"University Hospital, Strasbourg, France","startDate":"2016-03-30","conditions":"Rheumatoid Arthritis, Insufficient Response to Methotrexate or Leflunomide","enrollment":286},{"nctId":"NCT04871191","phase":"PHASE3","title":"Study of Salvage Therapy to Treat Patients with Granulomatosis with Polyangiitis","status":"NOT_YET_RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2025-03","conditions":"Granulomatosis with Polyangiitis, Anti-neutrophil Cytoplasmic Antibody-associated Vasculitis","enrollment":42},{"nctId":"NCT06297096","phase":"PHASE3","title":"Study of the Efficacy of Nintedanib+Tocilizumab in Patients With Systemic Sclerosis and Interstitial Lung Disease","status":"NOT_YET_RECRUITING","sponsor":"National Institute of Geriatrics, Rheumatology and Rehabilitation, Poland","startDate":"2025-01-01","conditions":"Systemic Sclerosis, Interstitial Lung Disease","enrollment":86},{"nctId":"NCT03737708","phase":"PHASE4","title":"A Study Comparing Biologics + Methotrexate With Biologics + Tacrolimus in Patients With Rheumatoid Arthritis (RA)","status":"COMPLETED","sponsor":"Astellas Pharma Korea, Inc.","startDate":"2019-02-13","conditions":"Rheumatoid Arthritis (RA)","enrollment":21},{"nctId":"NCT06498089","phase":"PHASE4","title":"A Randomized, Controlled, Open-label, Multicenter Clinical Trial Comparing the Efficacy and Safety of a Precision Treatment Regimen Based on Clinical-molecular Phenotypes with a Conventional Treatment Regimen in the Treatment of Patients with Active Takayasu's Arteritis","status":"RECRUITING","sponsor":"Shanghai Zhongshan Hospital","startDate":"2024-06-28","conditions":"Takayasu Arteritis","enrollment":124},{"nctId":"NCT05489224","phase":"PHASE3","title":"A Study to Compare Efficacy and Safety of CT-P47 and RoActemra in Patients With Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Celltrion","startDate":"2022-09-14","conditions":"Rheumatoid Arthritis","enrollment":471},{"nctId":"NCT01242488","phase":"PHASE2","title":"Efficacy and Safety of CDP6038 in Patients With Rheumatoid Arthritis With an Unsuccessful Response to Anti-Tumor Necrosis Factor (Anti-TNF) Therapy","status":"COMPLETED","sponsor":"UCB Pharma","startDate":"2010-11","conditions":"Rheumatoid Arthritis","enrollment":221},{"nctId":"NCT05623592","phase":"PHASE2","title":"Methotrexate as Remission Maintenance Therapy After Remission-Induction With Tocilizumab and Glucocorticoids in Giant Cell Arteritis","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Bonn","startDate":"2022-11-23","conditions":"Giant Cell Arteritis","enrollment":52},{"nctId":"NCT02385110","phase":"PHASE2","title":"Alemtuzumab or Tocilizumab in Combination With Etoposide and Dexamethasone for the Treatment of Adult Patients With Hemophagocytic Lymphohistiocytosis","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2015-09-23","conditions":"Leukemia","enrollment":18},{"nctId":"NCT03155347","phase":"PHASE3","title":"An Efficacy and Safety Study of Subcutaneous Tocilizumab in Combination With Methotrexate (MTX) and as Monotherapy Versus MTX in Participants With Moderate to Severe Rheumatoid Arthritis With Inadequate Response to Current Disease-Modifying Antirheumatic Drug (DMARD) Therapy","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2017-08-02","conditions":"Rheumatoid Arthritis","enrollment":340},{"nctId":"NCT06048224","phase":"PHASE3","title":"Phase III Clinical Trial Comparing the Safety, Efficacy, and Immunogenicity of Recombinant Anti-interleukin-6 Receptor Humanized Monoclonal Antibody Injection in Combination With Methotrexate and Jamelor ® in the Treatment of Moderate to Severe Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Zhejiang Hisun Pharmaceutical Co. Ltd.","startDate":"2020-12-28","conditions":"Moderate to Severe Active Rheumatoid Arthritis","enrollment":669},{"nctId":"NCT05928754","phase":"NA","title":"Prospective CoHoRt Of Non-infectious Intermediate, pOsterior or panuveitiS","status":"NOT_YET_RECRUITING","sponsor":"Centre Hospitalier National d'Ophtalmologie des Quinze-Vingts","startDate":"2023-09","conditions":"Non-infectious Uveitis","enrollment":2000},{"nctId":"NCT05696106","phase":"","title":"Risk of Incident IMID in Patients Treated With Biologics and Immunosuppressive Drugs for a Single IMID","status":"UNKNOWN","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2023-04-02","conditions":"Inflammatory Disease","enrollment":750000},{"nctId":"NCT03699631","phase":"PHASE2","title":"PROACTIVE: Preventing Acute/Chronic GVHD With TocIlizumab Combined With GVHD Prophylaxis Post allogEneic Transplant","status":"COMPLETED","sponsor":"Medical College of Wisconsin","startDate":"2018-11-06","conditions":"Hematologic Malignancy","enrollment":29},{"nctId":"NCT01491815","phase":"PHASE4","title":"Active Conventional Therapy Compared to Three Different Biologic Treatments in Early Rheumatoid Arthritis With Subsequent Dose Reduction","status":"UNKNOWN","sponsor":"Karolinska Institutet","startDate":"2012-12-14","conditions":"Rheumatoid Arthritis","enrollment":812},{"nctId":"NCT02466581","phase":"PHASE4","title":"Dose Reduction for Early Rheumatoid Arthritis Patients With Low Disease Activity","status":"UNKNOWN","sponsor":"Karolinska Institutet","startDate":"2015-02-03","conditions":"Rheumatoid Arthritis","enrollment":25},{"nctId":"NCT03830203","phase":"PHASE3","title":"Comparative Study of BAT1806 to RoActemra® in Rheumatoid Arthritis Patients With Inadequate Response to Methotrexate","status":"COMPLETED","sponsor":"Bio-Thera Solutions","startDate":"2018-12-19","conditions":"Rheumatoid Arthritis","enrollment":621},{"nctId":"NCT05090410","phase":"PHASE3","title":"Efficacy and Safety of Selective JAK 1 Inhibitor Filgotinib in Active Rheumatoid Arthritis Patients With Inadequate Response to Methotrexate","status":"UNKNOWN","sponsor":"Atsushi Kawakami","startDate":"2021-03-03","conditions":"Rheumatoid Arthritis, JAK Inhibitor, IL-6 Inhibitor","enrollment":400},{"nctId":"NCT02608112","phase":"","title":"Study to Describe Real World Drug Retention Rate of the Tocilizumab at One Year","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2015-12-31","conditions":"Rheumatoid Arthritis","enrollment":291},{"nctId":"NCT01791153","phase":"PHASE3","title":"An Efficacy and Safety Study of Tocilizumab (RoActemra/Actemra) in Participants With Giant Cell Arteritis (GCA)","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2013-07-22","conditions":"Giant Cell Arteritis","enrollment":251},{"nctId":"NCT04157010","phase":"PHASE4","title":"Tocilizumab REMission in Early RA","status":"COMPLETED","sponsor":"University of Leeds","startDate":"2013-05","conditions":"Rheumatoid Arthritis","enrollment":20},{"nctId":"NCT02287922","phase":"PHASE2","title":"A Phase IIb Study for ALX-0061 Monotherapy in Subjects With Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Ablynx, a Sanofi company","startDate":"2015-03","conditions":"Rheumatoid Arthritis","enrollment":251},{"nctId":"NCT02569736","phase":"","title":"Characterization of the Effect of Tocilizumab in Vivo and in Vitro on T Follicular Helper Cells in Rheumatoid Arthritis Patients and Consequence on B Cells Maturation","status":"COMPLETED","sponsor":"Association Aquitaine de Recherche Clinique en Rhumatologie","startDate":"2014-09","conditions":"Arthritis, Rheumatoid, Tocilizumab, T-Lymphocytes, Helper-Inducer","enrollment":60},{"nctId":"NCT02046603","phase":"PHASE3","title":"A Study of Tocilizumab (RoActemra/Actemra) in Monotherapy or in Combination With Methotrexate or Other Non-Biologic DMARDs in Participants With Active Rheumatoid Arthritis and an Inadequate Response to Current Non-Biologic DMARD Therapy or the First Anti-TNF Biologic Agent","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2014-03-04","conditions":"Rheumatoid Arthritis","enrollment":162},{"nctId":"NCT01941095","phase":"PHASE3","title":"A Study of Subcutaneous Tocilizumab as Monotherapy and/or in Combination With Non-Biologic Disease Modifying Anti-Rheumatic Drugs (DMARDs) in Participants With Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2013-11-20","conditions":"Rheumatoid Arthritis","enrollment":100},{"nctId":"NCT02001987","phase":"PHASE3","title":"A Study of Tocilizumab (RoActemra) in Tocilizumab-Naive Participants With Rheumatoid Arthritis and Inadequate Response to Non-Biologic Disease-Modifying Antirheumatic Drugs (DMARDs) and/or Biologic Therapy","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2014-01","conditions":"Rheumatoid Arthritis","enrollment":139},{"nctId":"NCT03610217","phase":"NA","title":"Pragmatic Clinical Trials in Scleroderma","status":"UNKNOWN","sponsor":"University of West London","startDate":"2018-10","conditions":"Scleroderma, Systemic, Sclerosis, Systemic","enrollment":400},{"nctId":"NCT01918267","phase":"","title":"U-Act-After: An Observational Study on Long-Term Efficacy of Tight Control RoActemra/Actemra (Tocilizumab) and/or Methotrexate in Patients With Early Rheumatoid Arthritis Who Have Participated in the U-Act-Early Study (ML22497)","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2012-04-10","conditions":"Rheumatoid Arthritis","enrollment":226},{"nctId":"NCT02046616","phase":"PHASE3","title":"A Study of Subcutaneous (SC) Tocilizumab (RoActemra/Actemra) in Participants With Active Rheumatoid Arthritis (RA) and Inadequate Response to Disease-Modifying Anti-Rheumatic Drugs (DMARDs)","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2014-05-28","conditions":"Rheumatoid Arthritis","enrollment":133},{"nctId":"NCT01995201","phase":"PHASE3","title":"A Study of Subcutaneous RoActemra/Actemra (Tocilizumab) as Monotherapy or in Combination With Methotrexate or Other Non-Biologic DMARDs in Patients With Active Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2013-09","conditions":"Rheumatoid Arthritis","enrollment":401},{"nctId":"NCT01855789","phase":"PHASE3","title":"A Study of the Impact of Methotrexate (MTX) Discontinuation on the Efficacy of Subcutaneous (SC) Tocilizumab (TCZ) With MTX","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2013-11-07","conditions":"Rheumatoid Arthritis","enrollment":718},{"nctId":"NCT01063062","phase":"PHASE3","title":"A Study With Tocilizumab [RoActemra/Actemra] Monotherapy or in Combination With Methotrexate in Patients With Rheumatoid Arthritis (PICTURE)","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2010-02-28","conditions":"Rheumatoid Arthritis","enrollment":107},{"nctId":"NCT00535782","phase":"PHASE3","title":"A Study of the Effect of Tocilizumab on Markers of Atherogenic Risk in Patients With Moderate to Severe Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2007-10-31","conditions":"Rheumatoid Arthritis","enrollment":132},{"nctId":"NCT01007435","phase":"PHASE3","title":"A Study of Tocilizumab as Monotherapy and in Combination With Methotrexate Versus Methotrexate in Patients With Early Moderate to Severe Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2009-10-31","conditions":"Rheumatoid Arthritis","enrollment":1162},{"nctId":"NCT01941940","phase":"PHASE3","title":"A Study to Evaluate Efficacy of Tocilizumab Administered as Monotherapy or in Combination With Methotrexate and/or Other Disease Modifying Antirheumatic Drugs (DMARDs) in Rheumatoid Arthritis (RA) Participants","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2013-09-05","conditions":"Rheumatoid Arthritis","enrollment":227},{"nctId":"NCT01768572","phase":"PHASE3","title":"To Evaluate The Safety of SAR153191 (REGN88) and Tocilizumab Added to Other RA Drugs in Patients With RA Who Are Not Responding to or Intolerant of Anti-TNF Therapy (SARIL-RA-ASCERTAIN)","status":"COMPLETED","sponsor":"Sanofi","startDate":"2013-03","conditions":"Rheumatoid Arthritis","enrollment":202},{"nctId":"NCT01987479","phase":"PHASE3","title":"A Study on Safety and Efficacy of Tocilizumab (RoActemra/Actemra) Alone or in Combination With Non-Biologic Antirheumatics in Participants With Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2014-01-30","conditions":"Rheumatoid Arthritis","enrollment":150},{"nctId":"NCT00965653","phase":"PHASE1","title":"A Study of Subcutaneously Administered Tocilizumab in Patients With Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2009-08","conditions":"Rheumatoid Arthritis","enrollment":29},{"nctId":"NCT00109408","phase":"PHASE3","title":"A Study to Assess the Safety and Efficacy of Tocilizumab in Patients With Active Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2005-07","conditions":"Rheumatoid Arthritis","enrollment":673},{"nctId":"NCT00106522","phase":"PHASE3","title":"A Study to Assess the Effect of Tocilizumab + Methotrexate on Signs and Symptoms in Patients With Moderate to Severe Active Rheumatoid Arthritis Currently on Methotrexate Therapy","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2005-05","conditions":"Rheumatoid Arthritis","enrollment":499},{"nctId":"NCT01384461","phase":"","title":"An Observational Study of RoActemra/Actemra (Tocilizumab) in Combination With Methotrexate in Patients With Rheumatoid Arthritis (ACTIVATE)","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2011-01","conditions":"Rheumatoid Arthritis","enrollment":251},{"nctId":"NCT01878318","phase":"PHASE4","title":"A Study of The Effect of RoActemra/Actemra (Tocilizumab) in Combination With Methotrexate on Articular Damage in The Hand in Patients With Moderate to Severe Rheumatoid Arthritis Who Have an Inadequate Response to Non-Biological DMARDs","status":"WITHDRAWN","sponsor":"Hoffmann-La Roche","startDate":"2013-06","conditions":"Rheumatoid Arthritis","enrollment":""},{"nctId":"NCT01661140","phase":"PHASE4","title":"A Study of RoActemra/Actemra (Tocilizumab) in Combination With Methotrexate in Patients With Severe Active Rheumatoid Arthritis, Comparing Tapering Versus Maintaining the Methotrexate Dosage","status":"TERMINATED","sponsor":"Hoffmann-La Roche","startDate":"2012-09","conditions":"Rheumatoid Arthritis","enrollment":427},{"nctId":"NCT02837146","phase":"PHASE3","title":"Ultrasound as Imaging Biomarker of Early Response to Tocilizumab and Methotrexate in Very Early Rheumatoid Arthritis","status":"UNKNOWN","sponsor":"Maria Stoenoiu","startDate":"2015-12","conditions":"Rheumatoid Arthritis","enrollment":45},{"nctId":"NCT00642460","phase":"PHASE3","title":"A Study of RoActemra/Actemra (Tocilizumab) in Patients With Active Systemic Juvenile Idiopathic Arthritis (JIA)","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2008-05","conditions":"Juvenile Idiopathic Arthritis","enrollment":112},{"nctId":"NCT01034137","phase":"PHASE3","title":"A Study of Tocilizumab and Methotrexate in Combination or as Monotherapy in Treatment-Naïve Patients With Early Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2010-01","conditions":"Rheumatoid Arthritis","enrollment":317},{"nctId":"NCT02779114","phase":"PHASE3","title":"RETRO (REduction of Therapy in RA Patients in Ongoing Remission)","status":"UNKNOWN","sponsor":"University of Erlangen-Nürnberg Medical School","startDate":"2009-01","conditions":"Rheumatoid Arthritis","enrollment":318},{"nctId":"NCT01587989","phase":"PHASE3","title":"A Study of RoActemra/Actemra (Tocilizumab) With or Without Methotrexate in Patients With Mild to Moderate Rheumatoid Arthritis With an Inadequate Response to Methotrexate","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2012-02","conditions":"Rheumatoid Arthritis","enrollment":77},{"nctId":"NCT01399697","phase":"PHASE4","title":"A Study of RoActemra/Actemra (Tocilizumab) in Combination With Methotrexate Versus RoActemra/Actemra Monotherapy in Patients With Rheumatoid Arthritis and an Inadequate Response to Methotrexate","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2011-09","conditions":"Rheumatoid Arthritis","enrollment":261},{"nctId":"NCT02087696","phase":"PHASE4","title":"Uncontrolled Study to Evaluate Efficacy of Tocilizumab in Patients With Moderate or Severe Rheumatoid Arthritis","status":"UNKNOWN","sponsor":"Spanish Foundation of Rheumatology","startDate":"2014-05","conditions":"Arthritis, Rheumatoid","enrollment":122},{"nctId":"NCT00754572","phase":"PHASE3","title":"A Study to Assess the Effect of Tocilizumab Plus Methotrexate on Safety and Signs and Symptoms in Patients With Moderate to Severe Active Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2009-02","conditions":"Rheumatoid Arthritis","enrollment":418},{"nctId":"NCT02097524","phase":"PHASE1","title":"Single-dose Study to Describe the Pharmacodynamics (PD) and Safety of Sarilumab (REGN88/SAR153191) and Tocilizumab in Adults With Rheumatoid Arthritis (RA)","status":"COMPLETED","sponsor":"Regeneron Pharmaceuticals","startDate":"2014-03","conditions":"Rheumatoid Arthritis","enrollment":105},{"nctId":"NCT01120366","phase":"PHASE4","title":"Success of Tocilizumab in RA Patients With Remission Induction and Sustained Efficacy After Discontinuation","status":"COMPLETED","sponsor":"SURPRISE Study Group","startDate":"2009-10","conditions":"Rheumatoid Arthritis","enrollment":233},{"nctId":"NCT00845832","phase":"PHASE2","title":"A Study of Combination Treatment With MabThera (Rituximab) and RoActemra (Tocilizumab) Versus RoActemra in Patients With Rheumatoid Arthritis With an Incomplete Response to Methotrexate","status":"TERMINATED","sponsor":"Hoffmann-La Roche","startDate":"2009-03","conditions":"Rheumatoid Arthritis","enrollment":24},{"nctId":"NCT01251120","phase":"PHASE4","title":"A Study of RoActemra/Actemra (Tocilizumab) in Combination With DMARDs Versus Current Best Practice DMARD Therapy in Patients With Rheumatoid Arthritis","status":"TERMINATED","sponsor":"Hoffmann-La Roche","startDate":"2011-11","conditions":"Rheumatoid Arthritis","enrollment":2},{"nctId":"NCT01235507","phase":"PHASE3","title":"A Study of RoActemra/Actemra (Tocilizumab) in Combination With Methotrexate in Patients With Active Rheumatoid Arthritis Who Have an Inadequate Response to Disease-Modifying Antirheumatic Drugs (DMARDs) (ALABASTER)","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2011-02","conditions":"Rheumatoid Arthritis","enrollment":71},{"nctId":"NCT00720798","phase":"PHASE3","title":"An Extension Study of Tocilizumab (Myeloma Receptor Antibody [MRA]) in Patients Completing Treatment in Tocilizumab Core Studies","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2005-09","conditions":"Rheumatoid Arthritis","enrollment":2067},{"nctId":"NCT01010503","phase":"PHASE4","title":"A Study of Tocilizumab With or Without Methotrexate in Patients With Rheumatoid Arthritis.","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2009-06","conditions":"Rheumatoid Arthritis","enrollment":32},{"nctId":"NCT00810199","phase":"PHASE3","title":"A Study of Tocilizumab and Methotrexate Treatment Strategies (Adding Tocilizumab to Methotrexate Versus Switching to Tocilizumab) in Patients With Active Rheumatoid Arthritis With Inadequate Response to Prior Methotrexate Treatment","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2009-03","conditions":"Rheumatoid Arthritis","enrollment":556},{"nctId":"NCT01353859","phase":"PHASE3","title":"A Study of RoActemra/Actemra (Tocilizumab) in Combination With Methotrexate in Patients With Active Rheumatoid Arthritis Who Have an Inadequate Response to Non-biologic DMARDs","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2011-03","conditions":"Rheumatoid Arthritis","enrollment":39},{"nctId":"NCT01283971","phase":"PHASE4","title":"A Study of RoActemra/Actemra (Tocilizumab) Versus Adalimumab in Combination With Methotrexate (MTX) in Patients With Moderate to Severe Active Rheumatoid Arthritis And an Inadequate Response to Treatment With Only One Tumor Necrosis Factor (TNF)-Inhibitor","status":"TERMINATED","sponsor":"Hoffmann-La Roche","startDate":"2011-05","conditions":"Rheumatoid Arthritis","enrollment":96},{"nctId":"NCT00106535","phase":"PHASE3","title":"A Study to Assess the Effect of Tocilizumab + Methotrexate on Prevention of Structural Joint Damage in Patients With Moderate to Severe Active Rheumatoid Arthritis (RA)","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2005-01","conditions":"Rheumatoid Arthritis","enrollment":1196},{"nctId":"NCT01245452","phase":"NA","title":"Study of the Response and Cardiorespiratory Endurance in Early RA Patients Treated With Tocilizumab or Methotrexate","status":"COMPLETED","sponsor":"Patrick Durez","startDate":"2010-05","conditions":"Rheumatoid Arthritis","enrollment":30},{"nctId":"NCT01258712","phase":"PHASE3","title":"Study of Tocilizumab in Combination With Methotrexate for Treatment of Moderate to Severe Rheumatoid Arthritis Patients","status":"COMPLETED","sponsor":"Chugai Pharma Taiwan","startDate":"2010-12","conditions":"Rheumatoid Arthritis (RA)","enrollment":86},{"nctId":"NCT01163747","phase":"PHASE4","title":"A Study of the Effects of RoActemra/Actemra on Vaccination in Patients With Rheumatoid Arthritis on Background Methotrexate (VISARA)","status":"COMPLETED","sponsor":"Genentech, Inc.","startDate":"2010-09","conditions":"Rheumatoid Arthritis","enrollment":91},{"nctId":"NCT00531817","phase":"PHASE3","title":"A Study of Tocilizumab in Combination With DMARDs in Patients With Moderate to Severe Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2007-10","conditions":"Rheumatoid Arthritis","enrollment":619},{"nctId":"NCT01187563","phase":"","title":"A Study of Tocilizumab in Patients With Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Regeneron Pharmaceuticals","startDate":"2010-08","conditions":"Rheumatoid Arthritis","enrollment":16},{"nctId":"NCT01211834","phase":"PHASE3","title":"Efficacy and Safety of Tocilizumab in Combination With DMARDs in Patients With Moderate to Severe Rheumatoid Arthritis","status":"COMPLETED","sponsor":"JW Pharmaceutical","startDate":"2009-10","conditions":"Rheumatoid Arthritis","enrollment":90},{"nctId":"NCT00365001","phase":"PHASE1","title":"A Drug Interaction Study Between Tocilizumab, Methotrexate and Simvastatin on Patients With Rheumatoid Arthritis.","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"","conditions":"Rheumatoid Arthritis","enrollment":23},{"nctId":"NCT00106548","phase":"PHASE3","title":"A Study to Assess the Effect of Tocilizumab + Methotrexate on Signs and Symptoms in Patients With Moderate to Severe Active Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"","conditions":"Rheumatoid Arthritis","enrollment":623}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":27,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Actemra","Methotrexate"],"phase":"marketed","status":"active","brandName":"Tocilizumab plus methotrexate","genericName":"Tocilizumab plus methotrexate","companyName":"SURPRISE Study Group","companyId":"surprise-study-group","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Tocilizumab is not mentioned in the provided facts, so it cannot be included in the summary. However, based on the information, methotrexate (MTX) is an intervention studied in clinical trials for conditions such as Rheumatoid Arthritis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":11,"withResults":3},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}